🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Health Concern

The sexually transmitted infection are on the rise around the world, with data suggesting in excess of 82 million infections per year. Especially elevated rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the context of rising global incidence, escalating drug resistance and the extremely scarce available drugs at this time.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Results and Global Access

As per data detailed in a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves an injection and a pill. The trial included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Doctors treating patients have expressed positive views. The availability of a easy-to-administer therapy of this kind is seen as a "game-changer" for gonorrhoea control. This is considered crucial to reduce the burden of the disease for people and to prevent the spread of untreatable gonorrhoea worldwide.